Abstract
There is a rapidly increasing epidemic of type 2 diabetes in India and other Asian countries due to rapid urbanization and lifestyle changes occurring in the country. India faces several challenges in diabetes management, including a rising prevalence in urban and rural areas, lack of disease awareness among the public, limited health care facilities, high cost of treatment, and rising prevalence of diabetic complications. Current antidiabetic agents fail to address disease progression and are often associated with weight gain and risk of hypoglycemia.
Highlights
Prevalence of T2DM in IndiaThe prevalence of Type 2 diabetes is rising globally
A recent report by International Diabetes Federation (IDF) on the global scenario shows that the prevalence of diabetes in 2014 was 382 million and estimated to increase to an alarming 592 million by 2035.Nearly 80% of the diabetic population lives in the developing countries [1] and greater than 60% of world diabetes population will be in Asia [2]
Dapagliflozin, a potent and selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been shown to improve glycemic control in patients with type 2 diabetes when used as monotherapy [29,30,31] or in combination with metformin [32,33], sulfonylureas [34,35,36], thiazolidinedione [37], DPP4 inhibitors [38], or insulin [39]
Summary
Prevalence of T2DM in IndiaThe prevalence of Type 2 diabetes is rising globally. A recent report by International Diabetes Federation (IDF) on the global scenario shows that the prevalence of diabetes in 2014 was 382 million and estimated to increase to an alarming 592 million by 2035.Nearly 80% of the diabetic population lives in the developing countries [1] and greater than 60% of world diabetes population will be in Asia [2]. Dapagliflozin, a potent and selective SGLT2 inhibitor, has been shown to improve glycemic control in patients with type 2 diabetes when used as monotherapy [29,30,31] or in combination with metformin [32,33], sulfonylureas [34,35,36], thiazolidinedione [37], DPP4 inhibitors [38], or insulin [39]. The efficacy of dapagliflozin in lowering the plasma glucose concentration as add-on therapy has been examined in poorly controlled T2DM treated with metformin, sulfonylureas and pioglitazone.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Current Research in Diabetes & Obesity Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
